Leaders in Pharmaceutical Business Intelligence (LPBI) Group

#PMConf @AVIVA1950 @pharma_BI Cary Pfeffer, M.D., Partner, Third Rock Ventures IP can’t be reduced by other country unfair trade

#PMConf @AVIVA1950 @pharma_BI Pellini – CMS will take the lead partnerships early and often in clinical trials,

#PMConf @AVIVA1950 @pharma_BI Michael Pellini, M.D., Managing Partner, Section 32; Board Member, Personalized Medicine Coalition Patients and Consumers will force in five years figuring out – every diagnosis of cancer will be sequenced to interpret results and paid for

#PMConf @pharma_BI @AVIVA1950 Salveen Richter, Goldman Sachs Sequencing cost plunged, public investors placing funding in start ups even without return in the horizon, companies with multiple modalities spurring innovation – Europe vs US, China has no FDA ,talent from US China

#PMConf @pharma_BI @AVIVA1950 Michael Pellini, M.D., Managing Partner, Section 32; Board Member, Personalized Medicine Coalition Diagnostics component inside 4.8 Trillion in the therapeutics selection in the system as a whole Foundation Medicine saw Roche for International reach

#PMConf @pharma_BI @AVIVA1950 William A. Sahlman, Ph.D., Baker Foundation Professor, Harvard Business School Biotech IPO, VC, windows slam shut, drug failure – drivers and non Increasing return to scale: AI, NGS, screening, – foreign money, Tsinghua went back to China from CA

#PMConf @pharma_BI @AVIVA1950 William A. Sahlman, Ph.D., Baker Foundation Professor, Harvard Business School market – can it sustain the opportunity – winners and losers innovative financial models Biotech IPO, VC, windows slam shut, drug failure – drivers and non

#PMConf @pharma_BI @AVIVA1950 Salveen Richter, C.F.A., Vice President, Research Division, Goldman Sachs Europe successful in financing Health care in the US system must change – investment will flee, to fund pricing drug is key in changing the system CART Pricing is key

#PMConf @pharma_BI @AVIVA1950 Michael Pellini, M.D., Managing Partner, Section 32; Board Member, Personalized Medicine Coalition Impasse or Inflection Point? it s Inflection Point NOT an Impasse Diagnostics component inside 4.8 Trillion in the therapeutics selection in system

#PMConf @pharma_BI @AVIVA1950 Cary Pfeffer, M.D., Partner, Third Rock Ventures MS drug efficacy was in 50% non respondents 25% Genomic sequencing to identify patient populations – target therapy Mayocardia – drug in CVD for patients identified by Genomics Genomics develop drugs

#PMConf @pharma_BI @AVIVA1950 Michael Pellini, M.D., Managing Partner, Section 32; Board Member, Personalized Medicine Coalition Impasse or Inflection Point? it s Inflection Point NOT an Impasse

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana CMS Guideline: every test ordered must guide treatment otherwise not covered

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana Guidelines on ordering genomic testing, AI can assist providers, MDs need to catch up on a weekly basis companion diagnostics and pharmaceutical paid together SOCare is paid

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana show us any value as good value – avoiding patient going to MDs Office, Hospital, ER – cost increase due to Pharmacogenomics testing $5K per test

#PMConf @pharma_BI @AVIVA1950 Scott Ramsey, M.D., Ph.D., Full Member, Fred Hutchinson Cancer Research Center; Director, Hutchinson Institute for Cancer Outcomes Research Pricing of Testing NGS and Targeted therapy represent a threat to adoption of Genomics in Medicine

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana What test needed to be ordered? Patient stay healthy NGS $650 – $2000 in 2018, in 2016 it was $25,000 cost of testing, cost of drugs

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humana cost of doing the test vs not doing this test – assess value CMS – provide data on what is covered and what is not Humana: any missed opportunities, MD order tests of no impact MR

#PMConf @pharma_BI @AVIVA1950 Dr. Ramsey – Survival in this cohort NGS vs EGFR – improved survival 6 month longer, Increased survivals, why? cost of sequencing – #14 most influential – cost does not drive value #1 drug cost, out of pocket expense was the factor #2 survival

#PMConf @pharma_BI @AVIVA1950 Scott Ramsey, M.D., Ph.D., Full Member, Fred Hutchinson Cancer Research Center; Director, Hutchinson Institute for Cancer Outcomes Research Value and utility are interconnected cost effectiveness of NGS in melanoma: single gene testing, EGFR vs NGS

#PMConf @pharma_BI @AVIVA1950 Kristine Bordenave, M.D., F.A.C.P., Corporate Medical Director, Humanalabs, payers, providers, pharma — the GAP to be bridged opportunities to prevent and treat disease Payers, MDs, cost and impact, markers, Humana has a research division Use Tests

#PMConf @pharma_BI @AVIVA1950 MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition genetic profiling, adopt policy for mass deployment of NGS demonstrate value, payers needs little more that evidence exist for payer to cover

#PMConf @pharma_BI @AVIVA1950 Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily (an Alphabet company) Patient need to own the genome data not a Databank

#PMConf @pharma_BI @AVIVA1950 Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily (an Alphabet company) Diagnostics in use to keep patients OUT of hospitals – management of chronic diseases

#PMConf @pharma_BI @AVIVA1950 Luba Greenwood, J.D., Strategic Business Development and Corporate Ventures, Verily (an Alphabet company) treatment solution therapeutics except og Oncology threatment is a strugle in the genomics field and pharmacogenomics General Medicine: CVD DM

#PMConf @pharma_BI @AVIVA1950 Keith Stewart, M.B., CH.B., Carlson and Nelson Endowed Director, Center for Individualized Medicine, Mayo Clinic genomics for detection of predisposition, inherited Barriers to deploy genomics: Knowledge, readiness of providers, cost of uninsured,

#PMConf @pharma_BI @AVIVA1950 Sigal: Patient deserve right answers right choices, calls doctors on behave of patients treatments done out of the community in Academic hospitals – patients are scared to death. Patients are asking for options: Right testing, access to testing

#PMConf @pharma_BI @AVIVA1950 The 14th Annual Leadership in Personalized Medicine Award to Ellen V. Sigal, Ph.D., Chairperson, Founder, Friends of Cancer Research Patient Challenges: 90% are treated Community and they need a second opinion, insurance, access, clinical trials

#PMConf @pharma_BI @AVIVA1950 Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health Technologies: AI, Countries with platforms Regulatory framework, reproducibility of results Taking care of people,

#PMConf @pharma_BI @AVIVA1950 Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum 1985 minorities education all surveys conducted in English, Asian American access to affordable health care services to accommodate services for communities

#PMConf @pharma_BI @AVIVA1950 Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health community based organization 50 million improving healthcare access improve inclusion in science, no advancement in 45 years Hard to reach through – academic language

#PMConf @pharma_BI @AVIVA1950 Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health PM with focus on disparities, racialbiologic, socioecological Patient centered – raise health education Translation for interpretation Physicians&Patients

#PMConf @pharma_BI @AVIVA1950 Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. NHGRI @genome_gov Genomics data is of European dissents no diversity minority populations not represente sland populations not represented hispanics not

#PMConf @pharma_BI @AVIVA1950 Kimberly Popovits, @GenomicHealth proprietary test vs. test offered by all labs — different markets Utility agreed upon like “http://MedicalDevicesInnovation.org ” demonstrate a pathway of product development that was already followed

#PMConf @pharma_BI @AVIVA1950 Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health – Oncology, Breast cancer molecular diagnostics Genomic testing saved the Health care System billions of dollars Genomic testing will not be placebo, 12 years study controlled

#PMConf @pharma_BI @AVIVA1950 Julie Khani, President, American Clinical Laboratory Association FDA will establish a center for Diagnostics, proposal for pre-certification like in Medical devices congress is involved in the decision making

#PMConf @pharma_BI @AVIVA1950 Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine – ex Genetech/Roche Operate in regulated environment, how to establish a company for long term companion diagnostics

#PMConf @pharma_BI @AVIVA1950 Joseph V. Ferrara, CEO, Boston Healthcare Associates Regulatory action for reimbursement of test new categories of tests: new payment if Innovation, PLA codes, 45 months approval, CPT codes

Best Talk like last year by David King @LabCorp, keynote at #PMConf

#PMConf @pharma_BI @AVIVA1950 David King, J.D., Chairman, CEO, LabCorp Non respondent – further researched MDs understanding, confidence of results PM Promise: close education GAP, convene on VALUE for individual cases not populations assess value among initiatives PM

#PMConf @pharma_BI @AVIVA1950 Tom Miller, Managing Partner, GreyBird Ventures LLC algorithms are behind the firewall of the Hospital, for privacy. the patient’s identity is not of central point, privacy is the key

#PMConf @pharma_BI @AVIVA1950 #Brookings Radiology: SW used in detection of disease Personalized Medicine and AI Data mining of Text using AI Vital signs monitoring – providers can spot Arrhythmias earlier tagging images is a matual process

#PMConf @pharma_BI @AVIVA1950 Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, #Brookings Interest in AI and in particular: Health care large part of the economy

#PMConf @pharma_BI @AVIVA1950 Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche – Data on mutations Data falls short on Patient follow up (longitudinal data on Patients) curation of EMR IS NOT AN EASY OR AUTOMATED PROCESS i.e., IMAGES

#PMConf @pharma_BI @AVIVA1950 Tom Miller, Managing Partner, GreyBird Ventures LLC AI applied to capture unusual movement allowing to detect a forthcoming neurological event. Technologies used now @Roche

#PMConf @pharma_BI @AVIVA1950 Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient Patient engage in their care, involvement in interpretation og ONES OWN Genome sequence is ate most engaging

#PMConf @pharma_BI @AVIVA1950 Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage, cystic fibrosis patient “Better #advocate for a #Patient is the Patient him/herself”

Great Panel moderation by Toni Andreu scientific director of @EatrisEric

Enjoyed most learning about the leading evolution in Genomics in Israel, UK, Canada and Finland

Amazing International Panel: UE, Israel, UK, Canada, Finland

Great talk of a visionary in Management of Academic @PMWCintl

Great Confernec, 14th in one row

#PMConf @pharma_BI @AVIVA1950 Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine General Medicine: Metabolomics, biological systems vs GENOMICS Medical care w/genomic testing, MDs will call to tell patients future news

#PMConf @pharma_BI @AVIVA1950 Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority $300Miliion R&D sponsored clinical data on genomics, MDs are trained to place genomics data on EMR, epidemiology, sequencing of genetic diseases

#PMConf @pharma_BI @AVIVA1950 Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland Public sector is the majority of Health care systems, Expertise is as high as can be, entrepreneurship is on the rise

#PMConf @pharma_BI @AVIVA1950 Marc LePage, President, CEO, Genome Canada Social impact, adoption systems for focusing on rare diseases, following UK and US trends, 10 sites in Canada, aggregate the datethe National level, extract clinical data securely implementation expertise

#PMConf @pharma_BI @AVIVA1950 Tom Fowler, Ph.D., Deputy Chief Scientist, @GenomicsEngland Building infrastructure, education, future, National approach to genomic testing, built in a National lab, scaling research

#PMConf @pharma_BI @AVIVA1950 @ElizabethNabel @BWH #Science at its best #Genomics #Biology #tools #platforms #Oncologywith #genomics for #therapy as in 2018 #NobelPrize #CART #Therapy no full #reimbursement #TRANSVIVO #TRANSFUCTION #mRNA #therapies #Clinical #Education #NGS